Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panobinostat in metastatic hormone refractory prostate cancer
NCT00667862Phase 2Completed
- Sponsor
- Novartis
- Start
- Mar 2008
- Primary completion
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of panobinostat in prostate cancer (PCa), sponsored by Novartis. Primary endpoint: Percentage of Participants With Progression-Free Survival (PFS) Rate at 24 Weeks. Started Mar 2008; status: completed.
02
Drugs
panobinostat
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00667862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00667862.